DGI-046 Monitoring of Adherence to Treatment and Adverse Events in the Management of Patients with HIV Infection

Abstract

A112Eur J Hosp Pharm 2013;20(Suppl 1):A1-A238information was entered into a database (Access) and the adherence to treatment and incidence of adverse events was calculated.Results We analysed the adherence questionnaires of 659 patients, 74% of whom reported 100% adherence to treatment. Coadministered medicines may lead to poorer HAART adherence: patients taking polypharmacy showed medium-low adherence to treatment. Adherence was found to correlate inversely with the daily pill burden. In terms of adverse effects, we developed a pharmacovigilance system, reporting 15 adverse drug reactions, 27% of which were rated severe. We analysed physical changes, gastrointestinal disorders and neuropsychiatric symptoms associated with the following regimens: efavirenz/emtricitabine/tenofovir, emtricitabine/tenofovir + atazanavir/ritonavir, efavirenz/emtricitabine/tenofovir, emtricitabine/tenofovir + atazanavir/ritonavir, emtricitabine/tenofovir + darunavir/ritonavir, abacavir/lamivudine + emtricitabine/tenofovir + darunavir/ritonavir, abacavir/lamivudine + atazanavir/ritonavir, abacavir/lamivudine + darunavir/ritonavir. Our results showed that the regimens with darunavir correlated with a lower incidence of side effects and perception of physical changes. Conclusions The physician-pharmacist collaboration is an important support in monitoring adherence and adverse events related to HAART and contributes significantly to the optimal management of patients with HIV infection.No conflict of interest.Morphine, oxycodone and Fentanyl prescribing patterns in the local health authority oF Messina, italy